CDX-1401

BIOLOGICAL3 trials

Sponsors

Celldex Therapeutics, Yale University, Case Comprehensive Cancer Center

Conditions

Advanced MalignanciesAdvanced Triple Negative Breast CancerMalignant MelanomaMesotheliomaNon Small Cell Lung CancerNon-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Cancer

Phase 1

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

CompletedNCT00948961

Celldex TherapeuticsAdvanced Malignancies

Start: 2009-09-30End: 2014-02-28Updated: 2016-06-27

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

WithdrawnNCT02661100

Case Comprehensive Cancer CenterAdvanced Triple Negative Breast Cancer, Malignant Melanoma, Mesothelioma +3

Start: 2017-01-31End: 2018-07-31Updated: 2016-12-07

Phase 2

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

WithdrawnNCT02495636

Yale UniversityNon-Small Cell Lung Cancer

Start: 2015-07-31End: 2017-07-31Updated: 2017-06-22

Related Papers

New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.

2017-07-1328 citations